Genetic Analysis AS

Genetic Analysis AS

GEAN · ST · Healthcare / Diagnostics & Research

0.56NOK+0.01 (+1.82%)

Price History

Full chart

Market Stats

Previous Close0.55
Open0.53
Day Range0.51 – 0.56
52-Week Range0.42 – 0.90
Volume24.60K
Market Cap46.01M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.18
Dividend Yield0.00%
Beta2.08
50-Day Avg0.595
200-Day Avg0.6482

About

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Fecal Test, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples. It is also involved in the operation of service laboratory where customers can send samples for microbiome profiling analysis; and provision of bioinformatic analysis and custom panel services. The company was founded in 2008 and is headquartered in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Ronny Hermansen MSc
  • Employees18
  • HeadquartersUlvenveien 80B, Oslo, Norway, 0581, Sweden
  • Websitehttps://www.genetic-analysis.com

Leadership

  • Mr. Ronny Hermansen MScChief Executive Officer · b. 1963
  • Mr. Lars TillerHead of Operations
  • Ms. Christina CasenSenior Vice President of Clinical & Medical Affairs
  • Ms. Kari FuruHead of Commercial
  • Ms. Mira Halvorsen BørstadChief Commercial Officer

Financials

Income Statement

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.78M6.80M11.16M14.15M15.89M16.71M
Growth (%)-+17.65%+64.17%+26.73%+12.29%+5.20%
Cost of Revenue1.03M1.28M3.91M4.43M3.11M4.70M
Gross Profit4.75M5.52M7.26M9.72M12.77M12.01M
Gross Margin82.22%81.16%65.00%68.68%80.40%71.88%
Operating Expense25.52M34.39M35.44M32.92M26.46M22.39M
Operating Income-20.77M-28.87M-28.18M-23.21M-13.69M-10.38M
Operating Margin-359.33%-424.60%-252.47%-164.06%-86.15%-62.12%
EBITDA---23.32M-17.98M-9.17M-5.74M
EBITDA Margin---208.93%-127.13%-57.74%-34.37%
Net Income-22.14M-29.01M-28.27M-23.82M-14.77M-11.41M
Net Income Margin-382.99%-426.57%-253.28%-168.36%-92.97%-68.29%
R&D2.25M1.23M----
R&D as % of Total Revenue38.89%18.13%----
Interest Expense210.74K134.18K117.72K254.00K355.00K496.00K
Interest Expense % of Total Revenue3.65%1.97%1.05%1.80%2.23%2.97%

Balance Sheet

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets55.62M83.49M64.42M53.49M42.38M52.45M
Total Liabilities9.00M11.40M20.28M21.49M19.88M25.37M
Total Equity46.62M72.09M44.14M32.00M22.49M27.08M
Cash24.19M46.00M24.42M15.28M12.79M23.37M

Cash Flow

Currency: NOK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.56M-27.62M-19.46M-17.23M-11.62M2.40M
Capital Expenditure5.18M1.95M226.74K643.00K1.95M5.54M
Free Cash Flow-11.73M-29.57M-19.69M-17.88M-13.57M-3.13M
FCF to OCF178.94%107.07%101.17%103.73%116.76%-130.53%

Earnings

Report DateMay 13, 2022Aug 18, 2022Sep 30, 2022Feb 17, 2023May 25, 2023Aug 30, 2023Nov 29, 2023Feb 28, 2024May 29, 2024Aug 28, 2024Nov 27, 2024Feb 26, 2025May 28, 2025Sep 3, 2025Dec 3, 2025Feb 25, 2026Jun 3, 2026Sep 2, 2026
EPS Estimate------------------
EPS Actual-0.31-0.24-0.25-0.31-0.29-0.22-0.16-0.17-0.13-0.11-0.06-0.02-0.09-0.01-0.05-0.04-0.07-0.04
Surprise------------------
TimingPre-marketPre-market-Pre-marketPre-marketPre-market------------

Key Statistics & Ratios

Market Cap46.01M
Enterprise Value26.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.26
Price / Book1.60
EPS-0.18
Book Value0.30
Revenue (TTM)20.34M
Gross Profit (TTM)16.08M
EBITDA-12.36M
Profit Margin-63.53%
Operating Margin-37.95%
Return on Equity-48.35%
Return on Assets-15.51%
Shares Outstanding69.09M
Shares Float19.49M
Beta2.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%